OBJECTIVE: We sought to assess the glucose disposition index using an oral glucose tolerance test (OGTT; oDI) compared with the glucose disposition index measured from the combination of the euglycemic-hyperinsulinemic and hyperglycemic clamps (cDI) in obese pediatric subjects spanning the range of glucose tolerance. STUDY DESIGN: Overweight/obese adolescents (n = 185) with varying glucose tolerance (87 normal, 54 impaired, 31 with type 2 diabetes, and 13 with type 1 diabetes) completed an OGTT and both a hyperinsulinemic-euglycemic and a hyperglycemic clamp study. Indices of insulin sensitivity and β-cell function were calculated, and 4 different oDI estimates were calculated as the products of insulin and C-peptide-based sensitivity and secretion indices. RESULTS: Mirroring the differences across groups by cDI, the oDI estimates were greatest in normal glucose tolerance adolescents and lowest in type 2 diabetes mellitus and obese with type 1 diabetes mellitus adolescents. The insulin-based oDI estimates correlated with cDI overall (r ≥ 0.74, P < .001) and within each glucose tolerance group (r ≥ 0.40, P < .001). Also, oDI and cDI predicted 2-hour OGTT glucose similarly. CONCLUSIONS: The oDI is a simple surrogate estimate of β-cell function relative to insulin sensitivity that can be applied to obese adolescents with varying glucose tolerance in large-scale epidemiological studies where the applicability of clamp studies is limited due to feasibility, cost, and labor intensiveness.
OBJECTIVE: We sought to assess the glucose disposition index using an oral glucose tolerance test (OGTT; oDI) compared with the glucose disposition index measured from the combination of the euglycemic-hyperinsulinemic and hyperglycemic clamps (cDI) in obese pediatric subjects spanning the range of glucose tolerance. STUDY DESIGN: Overweight/obese adolescents (n = 185) with varying glucose tolerance (87 normal, 54 impaired, 31 with type 2 diabetes, and 13 with type 1 diabetes) completed an OGTT and both a hyperinsulinemic-euglycemic and a hyperglycemic clamp study. Indices of insulin sensitivity and β-cell function were calculated, and 4 different oDI estimates were calculated as the products of insulin and C-peptide-based sensitivity and secretion indices. RESULTS: Mirroring the differences across groups by cDI, the oDI estimates were greatest in normal glucose tolerance adolescents and lowest in type 2 diabetes mellitus and obese with type 1 diabetes mellitus adolescents. The insulin-based oDI estimates correlated with cDI overall (r ≥ 0.74, P < .001) and within each glucose tolerance group (r ≥ 0.40, P < .001). Also, oDI and cDI predicted 2-hour OGTT glucose similarly. CONCLUSIONS: The oDI is a simple surrogate estimate of β-cell function relative to insulin sensitivity that can be applied to obese adolescents with varying glucose tolerance in large-scale epidemiological studies where the applicability of clamp studies is limited due to feasibility, cost, and labor intensiveness.
Authors: George Alberti; Paul Zimmet; Jonathan Shaw; Zachary Bloomgarden; Francine Kaufman; Martin Silink Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: Valeriya Lyssenko; Peter Almgren; Dragi Anevski; Roland Perfekt; Kaj Lahti; Michael Nissén; Bo Isomaa; Björn Forsen; Nils Homström; Carola Saloranta; Marja-Riitta Taskinen; Leif Groop; Tiinamaija Tuomi Journal: Diabetes Date: 2005-01 Impact factor: 9.461
Authors: Miriam Cnop; Josep Vidal; Rebecca L Hull; Kristina M Utzschneider; Darcy B Carr; Todd Schraw; Philipp E Scherer; Edward J Boyko; Wilfred Y Fujimoto; Steven E Kahn Journal: Diabetes Care Date: 2007-03 Impact factor: 19.112
Authors: Sudha S Shankar; Adrian Vella; Ralph H Raymond; Myrlene A Staten; Roberto A Calle; Richard N Bergman; Charlie Cao; Danny Chen; Claudio Cobelli; Chiara Dalla Man; Mark Deeg; Jennifer Q Dong; Douglas S Lee; David Polidori; R Paul Robertson; Hartmut Ruetten; Darko Stefanovski; Maria T Vassileva; Gordon C Weir; David A Fryburg Journal: Diabetes Care Date: 2016-07-12 Impact factor: 19.112
Authors: Ron T Varghese; Chiara Dalla Man; Anu Sharma; Ivan Viegas; Cristina Barosa; Catia Marques; Meera Shah; John M Miles; Robert A Rizza; John G Jones; Claudio Cobelli; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2016-09-07 Impact factor: 5.958
Authors: Silva Arslanian; Laure El Ghormli; Morey H Haymond; Christine L Chan; Steven D Chernausek; Rachelle G Gandica; Rose Gubitosi-Klug; Lynne L Levitsky; Maggie Siska; Steven M Willi Journal: Pediatr Diabetes Date: 2020-03-03 Impact factor: 4.866
Authors: Silva Arslanian; Laure El Ghormli; Joon Young Kim; Fida Bacha; Christine Chan; Heba M Ismail; Lorraine E Levitt Katz; Lynne Levitsky; Jeanie B Tryggestad; Neil H White Journal: Diabetes Care Date: 2018-11-19 Impact factor: 19.112